A Randomized, Double-Blind, Placebo Controlled, Cross-Over Study to Evaluate the Efficacy, Safety and Tolerability of Daily Oral SCI-110 in Treating Adults with Tourette Syndrome
Фаза 2 – изследване на ефективността и дозировката
Заболявания:
Tourette's syndrome in adults (≥18 and ≤65 years) in out-patient care
Спонсор: Neurothera Labs Inc.
Налично на:
БГ
Обобщение
Trial status: Authorised
[CCI], [CCI], [CCI], [CCI], [CCI], [CCI], [CCI], Number of adverse events (AEs), number and rate of patients affected by AEs, SAEs, SUSARs/ADRs, AESIs and AEs leading to withdrawal at each visit., Absolute values of vital signs (blood pressure, heart rate) at each visit and change from baseline for each visit. Number and percentage of clinically significant abnormal values.
[CCI]
Описание
[CCI], [CCI], [CCI], [CCI], [CCI], [CCI], [CCI], Number of adverse events (AEs), number and rate of patients affected by AEs, SAEs, SUSARs/ADRs, AESIs and AEs leading to withdrawal at each visit., Absolute values of vital signs (blood pressure, heart rate) at each visit and change from baseline for each visit. Number and percentage of clinically significant abnormal values.
Кой може да участва
Age group: 18-64 years, 65+ years
Gender: Female, Male
Target enrollment: 56 participants
БГ
EN